argenx Appoints Steve Krognes to Board of Directors
On February 27, 2023, argenx announced the appointment of Steve Krognes as a non-executive director and chairperson of the Audit and Compliance Committee during an extraordinary general meeting of shareholders. This change is part of the company's long-term succession planning, resulting in the resignation of Werner Lanthaler from his previous roles. CEO Tim Van Hauwermeiren expressed confidence in Krognes’ financial and compliance expertise, and acknowledged Lanthaler's impactful contributions over eight years, which were instrumental in transforming argenx into a global immunology leader.
- Appointment of Steve Krognes provides strong financial and compliance expertise.
- Krognes' industry knowledge aligns with argenx's innovative mission.
- Resignation of Werner Lanthaler may raise concerns about leadership continuity.
February 27, 2023
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors. He will also become the chairperson of the Audit and Compliance Committee.
As a result of the appointment of Mr. Krognes, Werner Lanthaler has formally resigned as non-executive director of the Board of Directors and chairperson of the Audit and Compliance Committee to enable this important step in long-term succession planning.
“We welcome Steve to the Board and are confident that with his strong financial and compliance expertise and valuable industry knowledge, he possesses the ideal profile to support argenx on our innovative, entrepreneurial mission,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “I would also like to express my gratitude to Werner for his substantial contributions over the last eight years. His entrepreneurial spirit combined with his broad experience in finance and executive leadership within biopharma has helped guide us from a research and development company to a fully integrated, global immunology company.”
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Erin Murphy
emurphy@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
FAQ
What prompted the appointment of Steve Krognes to the board of argenx?
What role will Steve Krognes hold at argenx?
Who resigned from argenx's board during the meeting?
What impact might the board changes have on argenx?
